Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19 per Hanson, AL, Mulè, MP, Ruffieux, H, Mescia, F, Bergamaschi, L, Pelly, VS, Turner, L, Kotagiri, P, Göttgens, B, Hess, C, Gleadall, N, Bradley, JR, Nathan, JA, Lyons, PA, Drakesmith, H, Smith, KGC

B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination per Kotagiri, P, Mescia, F, Rae, WM, Bergamaschi, L, Tuong, ZK, Turner, L, Hunter, K, Gerber, PP, Hosmillo, M, Hess, C, Clatworthy, MR, Goodfellow, IG, Matheson, NJ, McKinney, EF, Wills, MR, Gupta, RK, Bradley, JR, Bashford-Rogers, RJM, Lyons, PA, Smith, KGC

Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development per Burrows, N, Bashford-Rogers, RJM, Bhute, VJ, Peñalver, A, Ferdinand, JR, Stewart, BJ, Smith, JEG, Deobagkar-Lele, M, Giudice, G, Connor, TM, Inaba, A, Bergamaschi, L, Smith, S, Tran, MGB, Petsalaki, E, Lyons, PA, Espeli, M, Huntly, BJP, Smith, KGC, Cornall, RJ, Clatworthy, MR, Maxwell, PH

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease per Bergamaschi, L, Mescia, F, Turner, L, Hanson, AL, Kotagiri, P, Dunmore, BJ, Ruffieux, H, De Sa, A, Huhn, O, Morgan, MD, Gerber, PP, Wills, MR, Baker, S, Calero-Nieto, FJ, Doffinger, R, Dougan, G, Elmer, A, Goodfellow, IG, Gupta, RK, Hosmillo, M, Hunter, K, Kingston, N, Lehner, PJ, Matheson, NJ, Nicholson, JK, Petrunkina, AM, Richardson, S, Saunders, C, Thaventhiran, JED, Toonen, EJM, Weekes, MP, Göttgens, B, Toshner, M, Hess, C, Bradley, JR, Lyons, PA, Smith, KGC

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses per Needham, EJ, Ren, AL, Digby, RJ, Norton, EJ, Ebrahimi, S, Outtrim, JG, Chatfield, DA, Manktelow, AE, Leibowitz, MM, Newcombe, VFJ, Doffinger, R, Barcenas-Morales, G, Fonseca, C, Taussig, MJ, Burnstein, RM, Samanta, RJ, Dunai, C, Sithole, N, Ashton, NJ, Zetterberg, H, Gisslén, M, Edén, A, Marklund, E, Openshaw, PJM, Dunning, J, Griffiths, MJ, Cavanagh, J, Breen, G, Irani, SR, Elmer, A, Kingston, N, Summers, C, Bradley, JR, Taams, LS, Michael, BD, Bullmore, ET, Smith, KGC, Lyons, PA, Coles, AJ, Menon, DK

Combined point-of-care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G spike variant per Mlcochova, P, Collier, D, Ritchie, A, Assennato, SM, Hosmillo, M, Goel, N, Meng, B, Chatterjee, K, Mendoza, V, Temperton, N, Kiss, L, James, LC, Ciazynska, KA, Xiong, X, Briggs, JAG, Nathan, JA, Mescia, F, Bergamaschi, L, Zhang, H, Barmpounakis, P, Demeris, N, Skells, R, Lyons, PA, Bradley, J, Baker, S, Allain, JP, Smith, KGC, Bousfield, R, Wilson, M, Sparkes, D, Amoroso, G, Gkrania-Klotsas, E, Hardwick, S, Boyle, A, Goodfellow, I, Gupta, RK, Baker, S, Dougan, G, Gupta, R, Lehner, PJ, Lyons, P, Matheson, NJ, Toshner, M, Weekes, MP, Brown, N, Curran, M, Palmar, S, Enoch, D, Chapman, D, Shaw, A

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report per Buckland, MS, Galloway, JB, Fhogartaigh, CN, Meredith, L, Provine, NM, Bloor, S, Ogbe, A, Zelek, WM, Smielewska, A, Yakovleva, A, Mann, T, Bergamaschi, L, Turner, L, Mescia, F, Toonen, EJM, Hackstein, C-P, Akther, HD, Vieira, VA, Ceron-Gutierrez, L, Periselneris, J, Kiani-Alikhan, S, Grigoriadou, S, Vaghela, D, Lear, SE, Török, ME, Hamilton, WL, Stockton, J, Quick, J, Nelson, P, Hunter, M, Coulter, TI, Devlin, L, CITIID-NIHR COVID-19 BioResource Collaboration, MRC-Toxicology Unit COVID-19 Consortium, Bradley, JR, Smith, KGC, Ouwehand, WH, Estcourt, L, Harvala, H, Roberts, DJ, Wilkinson, IB, Screaton, N, Loman, N, Doffinger, R, Lyons, PA, Morgan, BP, Goodfellow, IG, Klenerman, P, Lehner, PJ, Matheson, NJ